StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Seattle Genetics (SGEN) Grantred FDA Supplemental Biologics License Application and Grants Priority Review for ADCETRIS (Brentuximab Vedotin)
January 2, 2018 8:01 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Seattle Genetics (SGEN) Adcetris Price Raised 3.9% - SunTrust Robinson Humphrey
January 2, 2018 1:19 PM
FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
January 2, 2018 8:00 AM